While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus.

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply of the upcoming oral options will be the sector’s next great challenge.

Obesity drug market heats up in India; Novo Nordisk advances Wegovy launch from 2026 to coming months to challenge Eli ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Novo Nordisk will invest $1.09 billion in Brazil to enhance production of injectable drugs for obesity and diabetes. This ...

The Danish pharmaceutical company behind obesity drug Wegovy, Novo Nordisk, plans to invest US$1.09bn in expanding its ...

Novo Nordisk is investing 6.4 billion reais in Brazil to enhance their manufacturing of drugs like Ozempic. The expansion in ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

Novo Nordisk ) is going big in Brazil. The drugmaker behind Ozempic and Wegovy just dropped a $1.09 billion investment to ...